Topical Steroids in Management of Dry Eye Disease

被引:2
作者
Favre, Hayley [1 ]
Lahoti, Sejal [1 ]
Issa, Nasser [1 ]
Johnson, Daniel A. [1 ]
Kheirkhah, Ahmad [1 ]
机构
[1] Univ Texas Hlth San Antonio, Med Arts & Res Ctr, Long Sch Med, Dept Ophthalmol, 8300 Floyd Curl Dr, San Antonio, TX 78229 USA
关键词
Topical steroids; Cornea; Dry eye disease; LOTEPREDNOL ETABONATE 0.5-PERCENT; KERATOCONJUNCTIVITIS SICCA; INTRAOCULAR-PRESSURE; CORNEAL EPITHELIUM; MEIBOMIAN GLAND; CYCLOSPORINE-A; HLA-DR; PREVALENCE; METHYLPREDNISOLONE; PREDNISOLONE;
D O I
10.1007/s40135-020-00249-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose of ReviewTo review current literature on the use of topical steroids for treatment of both aqueous-deficient and evaporative subtypes of dry eye disease (DED).Recent FindingsRecent studies have shown that topical steroids are effective for the treatment of patients with moderate or severe DED who have failed to respond to more conservative measures. These medications are useful for patients with both aqueous-deficient and evaporative subtypes of DED. Although topical steroids are often used for a short period of time, patients with chronic ocular surface inflammation can benefit from long-term treatment. For this, low-potency steroids, such as loteprednol or fluorometholone, would be reasonable due to their reduced risk for increasing intraocular pressure. Topical steroids have proven beneficial in conjunction with other anti-inflammatory medications such as topical calcineurin inhibitors.SummaryAs inflammation plays an important role in pathogenesis of DED, topical steroids may be considered for patients with refractory disease.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 58 条
  • [1] The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: A clinical and immunocytochemical study
    Avunduk, AM
    Avunduk, MC
    Varnell, ED
    Kaufman, HE
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (04) : 593 - 602
  • [2] Baudouin C, 2002, ADV EXP MED BIOL, V506, P761
  • [3] The pathology of dry eye
    Baudouin, C
    [J]. SURVEY OF OPHTHALMOLOGY, 2001, 45 : S211 - S220
  • [4] Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation
    Boynton, Grace E.
    Raoof, Duna
    Niziol, Leslie M.
    Hussain, Munira
    Mian, Shahzad I.
    [J]. CORNEA, 2015, 34 (07) : 725 - 732
  • [5] Efficacy of Combined 0.05% Cyclosporine and 1% Methylprednisolone Treatment for Chronic Dry Eye
    Byun, Yeo-jue
    Kim, Tae-im
    Kwon, Sang Min
    Seo, Kyung Yul
    Kim, Sun Woong
    Kim, Eung Kweon
    Park, Woo Chan
    [J]. CORNEA, 2012, 31 (05) : 509 - 513
  • [6] Dry Eye Disease as an Inflammatory Disorder
    Calonge, Margarita
    Enriquez-de-Salamanca, Amalia
    Diebold, Yolanda
    Gonzalez-Garcia, Maria J.
    Reinoso, Roberto
    Herreras, Jose M.
    Corell, Alfredo
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2010, 18 (04) : 244 - 253
  • [7] Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study
    Chia, EM
    Mitchell, P
    Rochtchina, E
    Lee, AJ
    Maroun, R
    Wang, JJ
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2003, 31 (03) : 229 - 232
  • [8] Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF)
    Cocuzzi, E
    Szczotka, LB
    Brodbeck, WG
    Bardenstein, DS
    Wei, T
    Medof, ME
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (02) : 188 - 195
  • [9] Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
    Comstock, Timothy L.
    DeCory, Heleen H.
    [J]. INTERNATIONAL JOURNAL OF INFLAMMATION, 2012, 2012
  • [10] TFOS DEWS II Definition and Classification Report
    Craig, Jennifer P.
    Nichols, Kelly K.
    Akpek, Esen K.
    Caffery, Barbara
    Dua, Harminder S.
    Joo, Choun-Ki
    Liu, Zuguo
    Nelson, J. Daniel
    Nichols, Jason J.
    Tsubota, Kazuo
    Stapleton, Fiona
    [J]. OCULAR SURFACE, 2017, 15 (03) : 276 - 283